VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CELC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CELCCelcuity Inc.
$58.01$2.8B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
CELC logo

Celcuity Inc.

CELC
NASDAQ · Oncology Biotech
$58.01
At close - Nov 17, 4:00 PM EST - USD
Market Cap$2.83B
P/E-12.5x
52W High$151.02
Volume2.21M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

FDA Approval Fuels Leveraged Commercialization Pivot

Celcuity's FDA approval of gedatolisib (REVTORPYK) marks a pivotal transition from clinical to commercial stage, but the company's financial position is severely strained. Operating losses have widened to -$66.1M in 2026Q2, and total debt surged to $754.4M, driving shareholders' equity negative at -$12.8M.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

CELC price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

8/12 Beats

EPS beat 8 of last 12 quarters

02

Valuation risk

-136% Peers

P/E is 136% below peer median

03

Market leadership

RS 19 · Lag

Laggard (Underperforming 81% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 5

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
CELC-42.31%
S&P 500 (^GSPC)+7.21%
1-Year Return
CELC-37.10%
S&P 500 (^GSPC)+10.03%
3-Year Return
CELC+353.91%
S&P 500 (^GSPC)+43.07%
5-Year Return
CELC+240.24%
S&P 500 (^GSPC)+61.95%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$177M-58.4% YoY
Free cash flow FY25
-$154M-83.4% YoY
Operating margin FY25
-
ROIC (FY25)-80.4%
Avg ROIC 5Y-51.5%
ROE (TTM)-1522.5%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate8/12 (67%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 5, 2026
-$1.21+19.9%
vs -$1.51
—
vs $909,800
Q3 2026
Aug 13, 2026
-$1.44-24.1%
vs -$1.16
—
vs $4M
Q2 2026
May 14, 2026
-$0.97+6.7%
vs -$1.04
—
vs $3M
Q2 2026
Mar 25, 2026
-$0.97+8.5%
vs -$1.06
—
vs $1M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Defense World·1d ago
Celcuity, Inc. $CELC Stock Sold by AlTi Global Inc.

AlTi Global Inc. cut its holdings in shares of Celcuity, Inc. (NASDAQ: CELC) by 68.9% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,287 shares of the company's stock after selling 11,689 shares during the period. AlTi Global Inc.'s

Defense World·3d ago
Celcuity, Inc. $CELC Shares Newly Bought by ACT Capital Partners L.P.

ACT Capital Partners L.P. bought a new stake in shares of Celcuity, Inc. (NASDAQ: CELC) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 58,650 shares of the company's stock, valued at approximately $4,664,000. Celcuity accounts for about 3.0% of

GlobeNewsWire·Nov 9, 2026
Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

MINNEAPOLIS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review its supplemental New Drug Application (“sNDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally advanced or metastatic breast cancer (“ABC”) with a PIK3CA mutation, following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. The FDA assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of June 25, 2027.

Seeking Alpha·Nov 8, 2026
Celcuity Inc. (CELC) Q3 2026 Earnings Call Transcript

Celcuity Inc. ( CELC ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Jodi Sievers - Head of Investor Relations & Corporate Communications Brian Sullivan - Co-Founder, Chairman & CEO Vicky Hahne - Chief Financial Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Tara Bancroft - TD Cowen, Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Gil Blum - Needham & Company, LLC, Research Division Daniel Bronder - Cantor Fitzgerald & Co., Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Oliver McCammon - LifeSci Capital, LLC, Research Division Kalpit Patel - Wolfe Research, LLC Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the Celcuity Third Quarter 2026 Financial Results Call and Webcast. [Operator Instructions] This call is being recorded on Thursday, November 5, 2026.

Filtered for Celcuity Inc.More Headlines
04

Compare before deciding

Benchmark CELC against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Celcuity Inc. (CELC)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
CELC logoCELCCelcuity Inc.Current
$58.01$2.83B-12.49——-1522.54%—
RVMD logoRVMDRevolution Medicines, Inc.
$162.69$34.59B-18.69—-946.82%-91.93%—
KYMR logoKYMRKymera Therapeutics, Inc.
$121.52$10B-34.81-16.72%-341.87%-22.39%—
TNGX logoTNGXTango Therapeutics, Inc.
$22.11$3.6B-18.4948.29%—-30.34%—
PMVP logoPMVPPMV Pharmaceuticals, Inc.
$1.22$65.06M-0.91——-110.22%—
AGEN logoAGENAgenus Inc.
$6.21$258.6M18.4110.37%20.98%——

Compare CELC vs Peers

Celcuity Inc. (CELC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RVMD

Most directly comparable listed peer for CELC.

Scale Benchmark

vs LLY

Larger-name benchmark to compare CELC against a more recognizable public peer.

Peer Set

Compare Top 5

vs RVMD, KYMR, TNGX, PMVP

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

CELC SEC Filings & Documents

Celcuity Inc. (CELC) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 26, 2026·SEC

Material company update

Aug 13, 2026·SEC

Material company update

Jul 15, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 26, 2026·SEC

FY 2025

Mar 31, 2025·SEC

FY 2024

Mar 27, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 13, 2026·SEC

FY 2026

May 14, 2026·SEC

FY 2025

Nov 13, 2025·SEC

Get notified when CELC posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

CELC Frequently Asked Questions

Celcuity Inc. (CELC) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is CELC profitable?

No. Celcuity Inc. (CELC) reported a net loss of $256.0M over the trailing twelve months.

Dividend & Returns
What is CELC's return on equity?

Celcuity Inc. (CELC) had a return on equity (ROE) of -1522.5% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Celcuity Inc.'s free cash flow?

Celcuity Inc. (CELC) had negative free cash flow of $213.5M over the trailing twelve months.

What if you invested $1,000 in CELC back in 2015?

Total return calculator · dividends reinvested · 11+ years of data

See returns →